Valneva plunges then recovers: what's really happening with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that rollercoaster rides are part of the daily grind. But what happened to Valneva this week is enough to make even the most seasoned investors wince. The stock brutally broke below €4.35, flirting with €3.89 before showing some signs of a rebound. A jolt like this always causes a stir among retail investors. So, what's really behind this latest reversal?
Solid financial results, but a fickle market mood
Let's put things in perspective. According to the financial results released a few days ago, the company's balance sheet is solid. Revenues are there, cash flow is healthy, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was probably hoping for a more aggressive outlook or more spectacular announcements regarding the progress of the famous Lyme disease vaccine.
But here, we're talking about science, not magic. Thomas Lingelbach, the CEO, repeats this every time he speaks: developing preventive vaccines against infectious diseases isn't something that happens overnight. VLA15 (that's the name of their Lyme disease candidate) is probably the most closely watched asset in the industry, because if it succeeds, it will be the first modern-day "cash cow" against this disease. But until it gets the final green light, the stock price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and the expectations
Let's not forget where we came from. With VLA2001, Valneva proved it could play with the big boys. This inactivated virus vaccine, used particularly in strict protocols, was a much-needed breath of fresh air. For those following the regulatory side, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains an important benchmark for evaluating real-world effectiveness.
But today, the market has a very short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines anymore. They want something new, something disruptive. And right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the still-ongoing maturation of its Lyme pipeline. This is often the tunnel where stocks suffer the most because traders dislike uncertainty. They prefer blockbuster quarterly announcements over quiet waiting periods.
Reasons to be optimistic (or not) going forward
So, what should you do if you have Valneva in your portfolio or are eyeing the stock? Here are a few points worth considering:
- Cash and visibility: The company has secured funding and partnerships. It's not going to disappear tomorrow. The financial results confirm this: there's enough substance to stay the course until the next major milestones.
- The Lyme timeline: VLA15 is the primary catalyst. Upcoming data readouts, if positive, could literally send the stock soaring. It's a binary situation, but with enormous potential.
- Thomas Lingelbach's experience: He's no novice. He's navigated far more severe storms than this minor market chill. His strategy, focused on developing preventive vaccines, remains consistent.
In the stock market, emotions are often amplified with this type of stock. The drop below €4.35 triggered stop-losses and automatic sell-offs, which mechanically amplified the movement. That's classic. What's more interesting is to see if the stock can stabilise above this psychological threshold in the coming sessions. If it does, the technical rebound could be just as brutal as the fall.
Let's be honest, betting on Valneva today means betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on during the uncertain phases for VLA2001 remember: when the science delivers, the market eventually follows.